Sonnet BioTherapeutics SONN 深 沪
已收盘 10-17 16:00:00 美东时间
3.63
-0.100
-2.68%
华盛通- 最 高3.79
- 今 开3.73
- 成交量 21.62万股
- 最 低 3.4801
- 昨 收 3.73
- 总市值 1149.19万
- 52周最高 19.30
- 市盈率 静 --
- 换手率 6.83%
- 52周最低 1.08
- 委 比 23.78%
- 总股本 316.58万
- 历史最高 329609.28
- 量 比 0.50
- 振 幅 8.31%
- 历史最低 1.08
- 每 手 1
- 风险率 3.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sonnet BioTherapeutics Collaborates With Spanios On Non-Clinical Study Using NAM-Based PDT Platforms That Emulate TME Ex Vivo To Evaluate Effect Of SON-1010 In Soft Tissue Sarcoma
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms that emulate the tumor
10-15 22:05
Sonnet to Present at the MedInvest Biotech & Pharma Conference
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announces that Interim CEO Raghu Rao will present at the MedInvest Biotech & Pharma Conference on September 25, 2025, at 9:40 AM PT in Palo Alto, California. A live webcast of the presentation will be available on the company's Events page under its Investors section. Sonnet specializes in developing immunotherapeutic drugs targeting the tumor microenvironment using its proprietary FHAB platform...
09-19 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock increased by 353.1% to $3.38 during Mond...
09-15 20:10
Why Check-Cap Shares Are Trading Higher By 183%; Here Are 20 Stocks Moving Premarket
Shares of Check-Cap Ltd. (NASDAQ:CHEK) rose sharply in pre-market trading. MBod...
09-15 17:45
Sonnet BioTherapeutics Q3 EPS $(0.95) Misses $(0.49) Estimate
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.49) by 93.88 percent. This is a 83.04 percent increase over losses of $(5.60) per
08-14 15:41
Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet BioTherapeutics announced the expansion of its SB221 clinical trial for platinum-resistant ovarian cancer (PROC). The expansion group, using the highest maintenance dose (E6 dose of 1200 ng/kg), has completed enrollment. Two out of three patients in the E6 dose escalation cohort showed partial responses, allowing further safety study in a larger population. Preliminary efficacy results are expected later this year. An E7 cohort with a main...
08-11 13:15
Sonnet Biotherapeutics Announces Expansion Of Its Phase 1b/2a Clinical Study Evaluating The Combination Of SON-1010 With Genentech's Atezolizumab In Patients With Platinum-Resistant Ovarian Cancer
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)Topline safety, cytokine, and
08-04 20:43
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Sonnet BioTherapeutics announced the expansion of its Phase 1b/2a SB221 study for platinum-resistant ovarian cancer (PROC) with its lead product, SON-1010 (IL12-FHAB), in combination with atezolizumab. The study has completed enrollment at the highest maintenance dose (E6 dose of 1200 ng/kg), with two out of three patients showing partial responses. A new E7 cohort has been added to evaluate a 25% higher dose, and top-line data are expected in la...
08-04 12:40
IOSG：加密货币储备经济模型大解构，微策略可复制吗？
（来源：吴说） 作者：Mario Chow @IOSG 原文链接：https://mp.weixin.qq.com/s/BaVW7IWSCFaqXdRIltr...
08-02 23:17
Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao
The latest update is out from Sonnet BioTherapeutics Holdings ( ($SONN) ). On J...
08-02 05:17
